EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Recombinant human alpha-N-acetylglucosamine-6-sulfatase delivered to Sanfilippo D mice with repeated intracerebroventricular injections corrects CNS pathology

Grant L Austin, Feng Wang, Steven Q Le, Alexander Sorensen iD, Shan Li, Lai C Foong, Srikanth Singamsetty, Jill Wood, Tsui-Fen Chou, Patricia I Dickson iD

PLOS One · 2025

DOI: 10.1371/journal.pone.0328941 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Grant L Austin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, United States of America. Hauptthemen laut MEDLINE: Mucopolysaccharidosis III, Recombinant Proteins, Chondroitinsulfatases. Die Arbeit nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NINDS NIH HHS, National Institute of Neurological Disorders and Stroke.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mucopolysaccharidosis type IIID (MPS IIID; Sanfilippo D) is caused by biallelic pathogenic variants in N-acetylglucosamine-6-sulfatase (GNS), which participates in catabolism of heparan sulfate (HS) glycosaminoglycans. Characterization of MPS IIID disease at a cellular level has not been robustly achieved. We used unbiased quantitative proteomics to establish a cellular phenotype for MPS IIID mice. Recombinant human GNS (rhGNS), a variant of which previously demonstrated single dose efficacy in MPS IIID human fibroblasts and in MPS IIID neonatal mice, was used to establish a repeat dosing schedule to treat MPS IIID mice. Adult Gns KO mice or heterozygous carriers were treated via intracerebroventricular (ICV) injections and received 3, 30, or 200 μg rhGNS in 4 doses over 2 weeks or vehicle. Twenty-four hours after the final dose, HS in brain and CSF showed dose-dependent reductions, reaching carrier levels in the higher dose groups. Furthermore, the proteomic perturbations that we described were corrected by rhGNS treatment. Next, Gns KO or carrier adult mice were treated via ICV and received 3, 30 or 200 μg rhGNS or vehicle once every two weeks (Day 1, 15, 29, 43, 57, 71, 85) and were euthanized on day 91. Following treatment, total HS and MPS IIID-specific HS (GlcNAc6S) showed dose-dependent reductions in brain and CSF and markers of neuroinflammation were substantially reduced. ICV enzyme replacement therapy with rhGNS restores CNS pathology of adult MPS IIID mice even with treatment at 14-day intervals, demonstrating preclinical efficacy for MPS IIID.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mucopolysaccharidosis IIIRecombinant ProteinsChondroitinsulfatasesAnimalsHumansMiceMice, KnockoutInjections, IntraventricularHeparan SulfateEnzyme Replacement TherapyBrainDisease Models, AnimalMale

Substanzen

Recombinant ProteinsChondroitinsulfatasesHeparan Sulfate

Autor:innen und Institutionen

  • Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, United States of America.
  • Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, California, United States of America.
  • Phoenix Nest Inc., Brooklyn, New York, United States of America.
  • Proteome Exploration Laboratory, Beckman Institute, California Institute of Technology, Pasadena, California, United States of America.

ORCID-Profile: Alexander Sorensen, Patricia I Dickson

Förderung

  • NIAID NIH HHS
  • NINDS NIH HHS
  • National Institute of Neurological Disorders and Stroke
  • National Institute of Allergy and Infectious Diseases

Zitieren

APA

Austin, G. L., Wang, F., Le, S. Q., Sorensen, A., Li, S., Foong, L. C., Singamsetty, S., Wood, J., Chou, T. F., & Dickson, P. I. (2025). Recombinant human alpha-N-acetylglucosamine-6-sulfatase delivered to Sanfilippo D mice with repeated intracerebroventricular injections corrects CNS pathology. PLOS One. https://doi.org/10.1371/journal.pone.0328941

Vancouver

Austin GL, Wang F, Le SQ, Sorensen A, Li S, Foong LC, et al. Recombinant human alpha-N-acetylglucosamine-6-sulfatase delivered to Sanfilippo D mice with repeated intracerebroventricular injections corrects CNS pathology. PLOS One. 2025. doi:10.1371/journal.pone.0328941

BibTeX
@article{Austin2025,
  author = {Austin, Grant L and Wang, Feng and Le, Steven Q and Sorensen, Alexander and Li, Shan and Foong, Lai C and Singamsetty, Srikanth and Wood, Jill and Chou, Tsui-Fen and Dickson, Patricia I},
  title = {Recombinant human alpha-N-acetylglucosamine-6-sulfatase delivered to Sanfilippo D mice with repeated intracerebroventricular injections corrects CNS pathology},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0328941}
}
Kostenlos starten →